Nanox Files 2023 Annual Report on Form 20-F
Nanox Files 2023 Annual Report on Form 20-F
PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission ("SEC") on April 22, 2024. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at https://www.sec.gov/ and on the Company's website at https://www.nanox.vision/ under "Financials" in the Investors section.
以色列PETACH TIKVA，2024年4月22日（GLOBE NEWSWIRE）——創新醫學成像技術公司NANO-X IMAGING LTD（“Nanox” 或 “公司”，納斯達克股票代碼：NNOX）今天宣佈，它已於2024年4月22日向美國證券交易委員會（“SEC”）提交了截至2023年12月31日財年的20-F表年度報告。20-F表年度報告包含公司經審計的合併財務報表，可在美國證券交易委員會的網站上訪問 https://www.sec.gov/ 並在公司的網站上 https://www.nanox.vision/ 在 “投資者” 部分的 “財務” 下。
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, at IR@nanox.vision.
公司將應要求免費向股東提供包含經審計的合併財務報表的年度報告的紙質副本。申請應發送至投資者關係部，電子郵件地址爲 IR@nanox.vision。
About Nanox
關於 Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox's vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox's subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox's products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.
Nanox（納斯達克股票代碼：NNOX）專注於應用其專有的醫學成像技術和解決方案，使診斷藥物在全球範圍內更容易獲得和負擔得起。Nanox的願景是增加常規醫學成像技術和流程的可及性，降低成本並提高其效率，以改善早期發現和治療，Nanox認爲這是幫助人們獲得更好的健康結果並最終挽救生命的關鍵。Nanox生態系統包括Nanox.arc——一種具有成本效益且用戶友好的多源數字斷層合成系統；一套基於人工智能的算法，可增強常規CT成像的讀數，以突出通常與慢性病相關的早期症狀（Nanox.AI）；基於雲的基礎架構（nanox.Cloud）；以及通過Nanox的子公司USARAD Holdings Inc.提供的專有去中心化市場，爲放射學和心臟病學專家提供遠程訪問；以及全面的遠程放射學服務平台（Nanox.Marketplace）。Nanox 的產品和服務共同創造了一個全球性、創新的全面解決方案，將從掃描到診斷的醫學成像解決方案連接起來。欲了解更多信息，請訪問 www.nanox.vision。
Contacts
聯繫人
Media Contact:
Ben Shannon
ICR Westwicke
NanoxPR@icrinc.com
媒體聯繫人：
本·香農
ICR Westwicke
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com
投資者聯繫人：
邁克·卡瓦諾
ICR Westwicke
mike.cavanaugh@westwicke.com